Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for ...

After disclosing a security breach last week concerning “a limited number of internal IT systems,” details on the cyber ...

With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line ...

In another Novo Nordisk manufacturing update, the company announced locally that it will invest 200 million yuan ($29 million ...

While describing the new import approval as a “tremendous step toward making prescription drugs affordable for all Coloradans ...

TV spot for Exdensur, stepping up promotion of an asthma drug that th | GSK has launched the first direct-to-consumer TV spot ...

With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since ...

As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business.  | ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

Recipharm has sketched out a “multi-million-dollar” investment in its U.S. manufacturing operations as part of a move to ...

U.S. pharmaceutical lobby group PhRMA has launched a new ad offensive that looks to highlight the American life sciences ...

Stealth BioTherapeutics is looking to put its tumultuous path behind it with a new name. | Stealth BioTherapeutics is looking ...